Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (GMAB)
NASDAQ:GMAB
GMAB Stock Chart & Stats
$28.84
-$0.14(-0.65%)
At close: 4:00 PM EST
$28.84
-$0.14(-0.65%)
Day’s Range― - ―
52-Week Range$17.24 - $33.65
Previous CloseN/A
Volume229.76K
Average Volume (3M)2.72M
Market Cap
$17.92B
Enterprise ValueN/A
Total Cash (Recent Filing)$18.37B
Total Debt (Recent Filing)$937.88M
Price to Earnings (P/E)14.5
Beta0.44
Next Earnings
Feb 25, 2026EPS Estimate
0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.65
Shares Outstanding642,063,500
10 Day Avg. Volume2,425,742
30 Day Avg. Volume2,723,436
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$40.80Price Target Upside41.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessPetosemtamab + chemo delivers highly promising results in 1L and 2L mCRC, appearing superior to those observed with cetuximab + FOLFOX and panitumumab + FOLFOX in Phase 3 trials.
Product PotentialPetosemtamab's market opportunity in head and neck cancer alone could exceed $3B annually, highlighting significant growth potential.
Strategic AcquisitionMerus Acquisition Bolsters Genmab's Late-Stage Pipeline, accelerating its shift from a royalty to a wholly owned model with long-term growth potential.
Bears Say
Acquisition CostsThe $8B Merus deal is sizable and carries significant operating expenses and interest expense dilution in the initial years following the acquisition.
Competitive LandscapeThe competitive landscape is expanding with several competitors providing updates with ADC programs in platinum resistant ovarian cancer.
Financial RisksRisks include slowing DARZALEX sales, failure to obtain DARZALEX label extensions, and negative readouts from DARZALEX trials.
Genmab News
GMAB FAQ
What was Genmab A/S’s price range in the past 12 months?
Genmab A/S lowest stock price was $17.23 and its highest was $33.65 in the past 12 months.
What is Genmab A/S’s market cap?
Genmab A/S’s market cap is $17.92B.
When is Genmab A/S’s upcoming earnings report date?
Genmab A/S’s upcoming earnings report date is Feb 25, 2026 which is in 109 days.
How were Genmab A/S’s earnings last quarter?
Genmab A/S released its earnings results on Nov 06, 2025. The company reported $0.646 earnings per share for the quarter, the consensus estimate of $0.646 by $0.
Is Genmab A/S overvalued?
According to Wall Street analysts Genmab A/S’s price is currently Undervalued.
Does Genmab A/S pay dividends?
Genmab A/S does not currently pay dividends.
What is Genmab A/S’s EPS estimate?
Genmab A/S’s EPS estimate is 0.44.
How many shares outstanding does Genmab A/S have?
Genmab A/S has 642,063,500 shares outstanding.
What happened to Genmab A/S’s price movement after its last earnings report?
Genmab A/S reported an EPS of $0.646 in its last earnings report, expectations of $0.646. Following the earnings report the stock price went down -1.199%.
Which hedge fund is a major shareholder of Genmab A/S?
Currently, no hedge funds are holding shares in GMAB
Genmab Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$40.80 (41.47% Upside)
$40.80 (41.47% Upside)
Blogger Sentiment
Bullish
GMAB Sentiment 66%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 425.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.30%
12-Months-Change
Fundamentals
Return on Equity
26.08%
Trailing 12-Months
Asset Growth
16.47%
Trailing 12-Months
Company Description
Genmab A/S
Genmab (GMAB) is a leading international biotechnology company specializing in the development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab focuses on creating innovative treatments that harness the body's immune system to combat malignancies. The company is known for its proprietary technologies, such as the DuoBody platform, which enables the development of bispecific antibodies, and has a robust pipeline of product candidates, including its flagship drug, Darzalex (daratumumab), used in multiple myeloma treatment.
GMAB Company Deck
GMAB Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial performance and promising clinical trial results, particularly for EPKINLY and Rina-S. The company is strategically investing in its pipeline and expanding its market presence. However, challenges such as the discontinuation of HexaBody-OX40 and potential regulatory hurdles were noted.View all GMAB earnings summariesGMAB Stock 12 Month Forecast
Average Price Target
$40.80
▲(41.47% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.23% Mutual Funds
<0.01% Other Institutional Investors
98.89% Public Companies and Individual Investors